請用此 Handle URI 來引用此文件: http://hdl.handle.net/11455/68834
標題: CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells
作者: Lee, J.C.
Chou, L.C.
Huang, C.H.
Chung, J.G.
Huang, L.J.
Lee, K.H.
Hung, M.C.
Way, T.D.
Kuo, S.C.
關鍵字: Apoptosis
CHM-1
Death receptor 5
Ovarian cancer
p38
trail-induced apoptosis
death receptors
targeting death
intraperitoneal
ligand
activation
kinase
chemotherapy
paclitaxel
induction
期刊/報告no:: European Journal of Pharmacology, Volume 670, Issue 1, Page(s) 96-104.
摘要: Ovarian cancer is a leading cause of death due to neoplasm of the female genital tract. Treatment for advanced-stage disease remains limited, and an effective drug for ovarian cancer is urgently needed today. In the present study, MTT assay was used to evaluate the antiproliferative effect of the 2-(substituted phenyl)-6,7-methylenedioxyquinolin-4-one derivatives for developing new anti-ovarian cancer drugs. CHM-1 was the most active compound, and it exhibited potent antiproliferative activity against human ovarian cancer cells. CHM-1 inhibited the growth of SKOV3 cells and induced apoptosis in a concentration-dependent manner, but it was less cytotoxic to human diploid skin fibroblast Detroit 551 cells. The western blot experiments showed that CHM-1 caused the upregulation of death receptor (DR) 5 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Interestingly, CHM-1-mediated cellular apoptosis was found to be closely involved with the p38-mediated upregulation of DR5 expression. In an SKOV3 subcutaneous xenograft model, both CHM-1 and its phosphate, CHM-1-P caused a significant dose- and time-dependent tumor regression. Furthermore, CHM-1 inhibited tumor growth and prolonged the lifespan in the SKOV3 ip1/luc orthotopic xenograft model. Intravenous administration of CHM-1-P significantly prolonged the survival time in the SKOV3/ICR-Foxn1nu orthotopic xenograft model. Based on their excellent antitumor activity with the interesting mechanism of action, CHM-1 and CHM-1-P were considered new anti-ovarian cancer drug candidates. (C) 2011 Elsevier B.V. All rights reserved.
URI: http://hdl.handle.net/11455/68834
ISSN: 0014-2999
文章連結: http://dx.doi.org/10.1016/j.ejphar.2011.08.006
顯示於類別:期刊論文

文件中的檔案:
沒有與此文件相關的檔案。


在 DSpace 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。